+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

      Clinical journal of the American Society of Nephrology : CJASN

      Young Adult, Treatment Outcome, Time Factors, genetics, Thrombomodulin, Risk Factors, Risk Assessment, Registries, Recurrence, Proportional Hazards Models, Polymorphism, Genetic, Phenotype, Pedigree, Mutation, Male, Kidney Transplantation, Kaplan-Meier Estimate, Infant, Newborn, Infant, Humans, therapy, mortality, immunology, Hemolytic-Uremic Syndrome, Genetic Testing, Genetic Predisposition to Disease, Gene Frequency, Female, Disease-Free Survival, DNA Mutational Analysis, Complement System Proteins, Complement Factor H, Complement C3, Chi-Square Distribution, blood, Autoantibodies, Antigens, CD46, Aged, 80 and over, Adult, Adolescent

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Most childhood cases are caused by Shiga toxin-producing bacteria. The other form, atypical HUS (aHUS), accounts for 10% of cases and has a poor prognosis. Genetic complement abnormalities have been found in aHUS. We screened 273 consecutive patients with aHUS for complement abnormalities and studied their role in predicting clinical phenotype and response to treatment. We compared mutation frequencies and localization and clinical outcome in familial (82) and sporadic (191) cases. In >70% of sporadic and familial cases, gene mutations, disease-associated factor H (CFH) polymorphisms, or anti-CFH autoantibodies were found. Either mutations or CFH polymorphisms were also found in the majority of patients with secondary aHUS, suggesting a genetic predisposition. Familial cases showed a higher prevalence of mutations in SCR20 of CFH and more severe disease than sporadic cases. Patients with CFH or THBD (thrombomodulin) mutations had the earliest onset and highest mortality. Membrane-cofactor protein (MCP) mutations were associated with the best prognosis. Plasma therapy induced remission in 55 to 80% of episodes in patients with CFH, C3, or THBD mutations or autoantibodies, whereas patients with CFI (factor I) mutations were poor responders. aHUS recurred frequently after kidney transplantation except for patients with MCP mutations. Results underline the need of genetic screening for all susceptibility factors as part of clinical management of aHUS and for identification of patients who could safely benefit from kidney transplant.

          Related collections

          Author and article information



          Comment on this article